Uzma Sajjad
Latest contributions
Shock: enhancing our pathways of care
21 May 2026 – From EuroPCR 2026
This session explores advancements in the management pathways for patients experiencing cardiogenic shock, particularly those complicating STEMI. It discusses patient characteristics, timing of PCI procedures, updated SCAI shock staging, representation in clinical trials, and angiographic findings in shockable out-of-hospital cardiac arrest cases, aiming to enhance clinical...
Inflammation and cardiovascular risk
21 May 2026 – From EuroPCR 2026
Exploring the interplay between inflammation and cardiovascular risk, this session reviews contemporary research on residual risk post-PCI, inflammatory markers in coronary artery disease especially in type 2 diabetes and ACS, and prognostic tools including lipoprotein(a) and systemic inflammation indices.
Treatment and prognostic stratification of ACS patients with cardiogenic shock
21 May 2025 – From EuroPCR 2025
This session focuses on treatment and prognostic stratification in ACS patients complicated by cardiogenic shock. Topics include mechanical CPR device performance, SCAI shock grade dynamics, hemorrhagic event predictors, ECMO-related strategies, and evaluation of BCIS conveyance algorithms for out-of-hospital cardiac arrest.
Coronary issues before, during and after TAVI
16 May 2024 – From EuroPCR 2024
This session presents a series of challenging clinical cases highlighting the complex interplay between coronary artery disease and transcatheter aortic valve implantation (TAVI). Attendees will witness real-world scenarios, including high-risk PCI with concomitant severe aortic stenosis, the management of degenerated aortic bioprostheses with the risk of...
Complex PCI in multivessel disease
14 May 2024 – From EuroPCR 2024
This session features selected clinical case submissions focused on complex PCI (Percutaneous Coronary Intervention) in patients with multivessel disease. Participants will learn about various challenging cases, including navigating heart failure, three-vessel disease with functional mitral regurgitation, complete revascularization assisted by Impella, and end-stage refractory angina. The...
